{"id":"capox-sox-folfox","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"60-80","effect":"Nausea and vomiting"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"30-40","effect":"Peripheral neuropathy"},{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Mucositis"},{"rate":"10-20","effect":"Hand-foot syndrome (capecitabine-based)"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These regimens combine 5-fluorouracil (or capecitabine/S-1 oral prodrugs) with oxaliplatin, a third-generation platinum compound. The fluoropyrimidines inhibit thymidylate synthase and incorporate into DNA/RNA, while oxaliplatin forms DNA cross-links, leading to apoptosis in rapidly dividing cancer cells. The combination provides synergistic cytotoxic activity against solid tumors.","oneSentence":"CAPOX/SOX/FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:51.532Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (metastatic and adjuvant settings)"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"},{"name":"Esophageal cancer"}]},"trialDetails":[{"nctId":"NCT07000253","phase":"PHASE2, PHASE3","title":"Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2026-01","conditions":"Esophageal Cancer, Gastric (Stomach) Cancer, Gastric Adenocarcinoma","enrollment":290},{"nctId":"NCT06888037","phase":"PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-03-31","conditions":"Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy","enrollment":55},{"nctId":"NCT03788226","phase":"PHASE3","title":"A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2019-02-01","conditions":"Gastric Cancer Stage III","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CAPOX/SOX/FOLFOX","genericName":"CAPOX/SOX/FOLFOX","companyName":"Fujian Cancer Hospital","companyId":"fujian-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CAPOX/SOX/FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents. Used for Colorectal cancer (metastatic and adjuvant settings), Gastric cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}